Meet 125 Mgmt Teams
ChannelCASTS
Long Story Short – CAR-T Therapy: The mythological two-headed cancer killing beast
Share
CAR-T Medicines for The Treatment of Cancer, Part 2
(Note: companies that could be impacted by the content of this article are listed at the base of the story (desktop version). This article uses third-party references to provide a bullish, bearish and balanced point of view; sources listed in the "Balanced" section)
Chimeric Antigen Receptor T cell therapy (CAR-T) is a gene therapy designed to harness the potency of antibodies and T-lymphocytes into one single medicine for the treatment of cancer. CAR-T therapy could be viewed as a “living anti-cancer drug” as the medicine itself consists of a living cell, which is genetically engineered as a pharmaceutical “chimera” to find and destroy cancer cells. The term chimera describes a monstrous being from Greek mythology composed from different animal parts. It appears in literature as a creature with two heads: a lion’s and a goat’s (see Figure 1 below). Like the creature from Greek mythology, a CAR-T medicine also has two heads: antibody binding domain and T-cell receptor (TCR) signaling domain.
Figure 1: According to Greek mythology, a Chimera was a hybrid with
parts from different animals. It consisted of a lion with a goat’s head and a
tail ending in snakes’ heads. In the Homer’s Iliad, a chimera is described as a
“fearsome beast snorting out the breath of terrible flame of bright fire”.
Source – Chimera, Greek Mythology, www.mythortruth.com
In science, the term chimera is often used to describe hybrids from different species, such as a virus with DNA sequences from different species, or a CAR-T drug construct consisting of an antibody fused to a T lymphocyte, combining the medical potency of an anti-cancer antibody with the cancer killing properties of a T lymphocyte. (read Part 1 of the CAR-T article series here)Hurdles Limiting Treatment of Solid Tumors
CAR-T cells are engineered to infiltrate the tumor mass and persist in it over long periods, which is required to kill cancer cells. However, objective tumor responses (tumor shrinkage) in solid tumors are frequently short-lived as the tumor microenvironment generate inhibitory signals rendering CAR-T cells inert. Inhibitory signals primarily come from a different type of T-lymphocytes known as “regulatory T cells” (Tregs), and from checkpoint molecules (CTLA-4, PD-1, LAG3, or TIM-3) expressed on the cell surface, which shut down CAR-T cells. When traditional CAR-T cells enter the tumor mass, they face physical and chemical barriers, they do not proliferate, are inhibited, and do not reach and kill cancer cells. These hurdles have been difficult to overcome. Another significant challenge for widespread adoption of CAR-T therapies is safety of these drugs. CAR-T treatment is associated with significant neurotoxicity and cytokine storms, which could be fatal in some treated patients.Hurdles Limiting Treatment of Solid Tumors
CAR-T cells are engineered to infiltrate the tumor mass and persist in it over long periods, which is required to kill cancer cells. However, objective tumor responses (tumor shrinkage) in solid tumors are frequently short-lived as the tumor microenvironment generate inhibitory signals rendering CAR-T cells inert. Inhibitory signals primarily come from a different type of T-lymphocytes known as “regulatory T cells” (Tregs), and from checkpoint molecules (CTLA-4, PD-1, LAG3, or TIM-3) expressed on the cell surface, which shut down CAR-T cells. When traditional CAR-T cells enter the tumor mass, they face physical and chemical barriers, they do not proliferate, are inhibited, and do not reach and kill cancer cells. These hurdles have been difficult to overcome. Another significant challenge for widespread adoption of CAR-T therapies is safety of these drugs. CAR-T treatment is associated with significant neurotoxicity and cytokine storms, which could be fatal in some treated patients.Biotechnology Innovations in CAR-T Area
In recent years, significant advances in CAR-T technologies have been implemented by various companies in the biotechnology industry. Although there are still hurdles to overcome, especially to develop efficacious CAR-T candidate medicines for the treatment of solid tumors, the industry continues to innovate. Better knowledge of T-cell receptor functions, improved understanding of anti-cancer immunology and a wider industry participation on these endeavors should generate better results in CAR-T human clinical trials. Allogene, Sorrento, Cellectis, Bellicum, CRISPR Therapeutics and Celyad are among innovating companies in the CAR-T area (read Part 1 of the CAR-T article series here).
Allogene (Nasdaq: ALLO) is developing “off-the-shelf” CAR-T medicines for the treatment of both blood cancers and solid tumors. The Company’s lead drug is UCART19, targeting CD19, a cell surface protein expressed on B-cells, including cancerous B-cells. Through a gene editing process, Allogene knocks out the natural T cell receptor from CARs to avoid “graft versus host disease” (GvHD). The main challenge for allogeneic CARs is the fact that the host (patient) immune system will reject the injected CAR-T cells. Allogeneic CARs come from a donor with a different genetic makeup (MHC - Major Histocompatibility Complex Antigen) than the host. Thus, the host’s immune system recognizes the CARs as foreign cells and could potentially kill them. In order to overcome this, Allogene knocks out the CD52 gene in CAR-T cells rendering them resistant to anti-CD52 antibody treatment. Anti-CD52 antibody treatment can therefore be used to suppress the host immune system and allow Allogene’s CAR-T cells to stay engrafted to achieve maximum potential efficacy.
Sorrento Therapeutics (Nasdaq: SRNE) is developing a CAR-T targeting CD38, a tumor associated antigen (TAA) selectively expressed on the surface of cancer cells, for the treatment of multiple myeloma (a type of blood cancer). Given that CD38 is expressed selectively on the surface of cancer cells, but not on normal cells, CD38 CAR-T might show minimal on-target/off-tumor toxicity (toxicity due to recognizing the correct target on the surface of normal cells). In November of last year, Sorrento announced results from Phase I trials on the use of CAR-T drugs targeting carcinoembryonic antigen (CEA) and prostate-specific membrane antigen (PSMA) for the treatment of solid tumors. Sorrento administered the CAR-T treatment utilizing a unique “Pressure-Enabled Drug Delivery” (PEDD) manufactured by TriSalus™ Life Sciences. PEDD technology overpowers the high-pressure characteristic of solid tumors, which limits penetration of the tumor mass by therapeutic agents. Using PEDD delivery, the number of CAR-T cells increased within the tumor mass. In the trial, two out of 4 pancreatic cancer patients showed complete disappearance of the liver metastasis (all patients showed reduced CEA levels on tumor cells). Median overall survival (OS) was 8.3 months in treated patients compared to only 3-6 months observed with standard of care treatment (historical data). Safety is another advantage of PEDD CAR-T treatment as it avoids neurotoxicity and cytokine release syndromes observed with systemic delivery of CAR-Ts.
Cellectis (Nasdaq: CLLS) is developing allogeneic (“off-the-shelf”) CAR-T product candidates using gene editing of T-cells derived from healthy donors. Gene editing is performed using “transcription activator-like effector nuclease” (TALEN), a gene editing nuclease-based technology allowing very precise and targeted gene modifications to the CAR-T cells. Cellectis’ lead product is currently being developed for the treatment of CD19-expressing hematological malignancies such as acute lymphoblastic leukemia (ALL). Cellectis approach of using an allogeneic, frozen, “off-the-shelf” T-cell based medicinal product has the potential to overcome limitations experienced with autologous therapies, such as very high costs and difficult manufacturing logistics. At the American Society of Hematology (ASH) Meeting in December of 2018, Cellectis presented preliminary results from Phase I studies of UCART19. The data demonstrated an 82% complete remission rate in treated acute lymphoblastic leukemia patients.
Bellicum Pharmaceuticals (Nasdaq: BLCM) is developing two CAR-T candidate medicines: BPX-601 and BPX-603. BPX-601 is an autologous CAR-T product candidate engineered using Bellicum’s proprietary “activation switch technology”, which is designed to treat solid tumors expressing prostate stem cell antigen (PSCA). The use of Bellicum’s activation switch technology results in a higher number of CAR-T cells penetrating the tumor mass and attacking cancer cells. Bellicum’s CAR-Ts persist for a longer time in the tumor mass, which increases the efficacy of this cancer treatment. Furthermore, the activation switch technology triggers an anti-cancer immune response by the host, modulating the tumor microenvironment. All these features combined are designed to increase treatment potency relative to traditional CAR-T therapies. In a Phase I/II clinical trial, nine out of 17 (53%) PSCA-positive pancreatic cancer patients showed CAR-T cells persisting for more than three weeks in the tumor mass. In the trial, 62% of the evaluable patients (8/13) had stable disease and three patients showed tumor shrinkage of 10% to 24%.
Bellicum’s BPX-603 is a dual-switch CAR-T product containing both the “activation switch technology” and a “safety switch technology”. The safety switch technology programs CAR-T cells to commit suicide (apoptosis) if the treated cancer patient shows any symptoms of toxicity. The activation switch controls the potency and efficacy of the CAR-T, whereas the safety switch minimizes the treatment’s potential toxicity. Both switches are turned on by administering oral drugs to cancer patients. The activation switch is turned on by intake of the oral drug rimiducid, whereas the safety switch is turned on by rapamycin, another oral drug. Bellicum’s BPX-603 is the first controllable dual-switch CAR-T candidate medicine. It targets solid tumors that express the “human epidermal growth factor receptor 2 antigen” (HER2).
CRISPR Therapeutics (Nasdaq: CRSP) is developing CTX130 as an allogeneic CRISPR/Cas9 gene-edited CAR-T cell therapy targeting CD70 expressing cancers, including hematological (blood) and solid tumors. According to the medical literature, CRISPR/Cas9 gene editing is faster, cheaper and easier to use than competing gene editing systems such as “transcription activator-like effector nuclease” (TALEN), and zinc-finger nucleases (ZFNs).
Celyad SA (Nasdaq: CYAD) is developing a different type of chimera. Celyad’s CAR-T medicines consist of an engineered T lymphocyte with a TCR fused to the NKG2D receptor, which is normally found on the surface of natural killer (NK) cells. This chimera has also two heads: NKG2D receptor and TCR. It differs from traditional CAR-Ts on the replacement of the “antibody binding domain” by NKG2D receptor. Like T lymphocytes, natural killer cells have also the ability to destroy cancer cells. The advantage of using the NKG2D receptor over an antibody binding domain is that NKG2D binds to multiple tumor antigens, instead of only one antigen as it is the case for an antibody. Celyad believes that NKG2D chimeras will be more potent than traditional CAR-Ts for the treatment of cancer.
In summary, the consensus among academics and industry experts is that research and development in CAR-T area will intensify in coming years, fueled not only by the current success of Gilead and Novartis, but also by recent data with fourth generation CAR-T medicines. They expect more biotechnology companies jumping into the fray, as the industry copes with the challenges of treating solid tumors with anti-cancer cell therapies, and innovation in this area accelerates.
Sources:
“Chimeric Antigen Receptor (CAR) T Cell Therapy for Malignant Pleural Mesothelioma (MPM)”. Cancers 2017, 9(9) p115
“Fine and Predictable Tuning of TALEN Gene Editing Targeting for Improved T Cell Adoptive Immunotherapy”. Molecular Therapy: Nucleic Acids Vol. 9 December 15, 2017.
“Programming CAR-T cells to kill cancer”. Nature Biomedical Engineering 2018, Vol 2, June 2018, p377-391
Switching on the green light for chimeric antigen receptor T-cell therapy. Clinical & Translational Immunology 2019, Vol 8, e1046
“CAR-T with License to Kill Solid Tumors in Search of a Winning Strategy”. International Journal of Molecular Sciences 2019, Vol 20, p1903
“Chimeric-antigen receptor T (CAR-T) cell therapy for solid tumors: challenges and opportunities”. Oncotarget 2015, Vol 8(52), p90521-90531
“Two-Dimensional Regulation of CAR-T Cell Therapy with Orthogonal Switches”. Molecular Therapy - Oncolytics 2018 Dec 20;12:124-137
“Therapeutic potential of CRISPR/Cas9 gene editing in engineered T-cell therapy”. Cancer Medicine 2019, DOI: 10.1002/cam4.2257Biotechnology Innovations in CAR-T Area
In recent years, significant advances in CAR-T technologies have been implemented by various companies in the biotechnology industry. Although there are still hurdles to overcome, especially to develop efficacious CAR-T candidate medicines for the treatment of solid tumors, the industry continues to innovate. Better knowledge of T-cell receptor functions, improved understanding of anti-cancer immunology and a wider industry participation on these endeavors should generate better results in CAR-T human clinical trials. Allogene, Sorrento, Cellectis, Bellicum, CRISPR Therapeutics and Celyad are among innovating companies in the CAR-T area (read Part 1 of the CAR-T article series here).
Allogene (Nasdaq: ALLO) is developing “off-the-shelf” CAR-T medicines for the treatment of both blood cancers and solid tumors. The Company’s lead drug is UCART19, targeting CD19, a cell surface protein expressed on B-cells, including cancerous B-cells. Through a gene editing process, Allogene knocks out the natural T cell receptor from CARs to avoid “graft versus host disease” (GvHD). The main challenge for allogeneic CARs is the fact that the host (patient) immune system will reject the injected CAR-T cells. Allogeneic CARs come from a donor with a different genetic makeup (MHC - Major Histocompatibility Complex Antigen) than the host. Thus, the host’s immune system recognizes the CARs as foreign cells and could potentially kill them. In order to overcome this, Allogene knocks out the CD52 gene in CAR-T cells rendering them resistant to anti-CD52 antibody treatment. Anti-CD52 antibody treatment can therefore be used to suppress the host immune system and allow Allogene’s CAR-T cells to stay engrafted to achieve maximum potential efficacy.
Sorrento Therapeutics (Nasdaq: SRNE) is developing a CAR-T targeting CD38, a tumor associated antigen (TAA) selectively expressed on the surface of cancer cells, for the treatment of multiple myeloma (a type of blood cancer). Given that CD38 is expressed selectively on the surface of cancer cells, but not on normal cells, CD38 CAR-T might show minimal on-target/off-tumor toxicity (toxicity due to recognizing the correct target on the surface of normal cells). In November of last year, Sorrento announced results from Phase I trials on the use of CAR-T drugs targeting carcinoembryonic antigen (CEA) and prostate-specific membrane antigen (PSMA) for the treatment of solid tumors. Sorrento administered the CAR-T treatment utilizing a unique “Pressure-Enabled Drug Delivery” (PEDD) manufactured by TriSalus™ Life Sciences. PEDD technology overpowers the high-pressure characteristic of solid tumors, which limits penetration of the tumor mass by therapeutic agents. Using PEDD delivery, the number of CAR-T cells increased within the tumor mass. In the trial, two out of 4 pancreatic cancer patients showed complete disappearance of the liver metastasis (all patients showed reduced CEA levels on tumor cells). Median overall survival (OS) was 8.3 months in treated patients compared to only 3-6 months observed with standard of care treatment (historical data). Safety is another advantage of PEDD CAR-T treatment as it avoids neurotoxicity and cytokine release syndromes observed with systemic delivery of CAR-Ts.
Cellectis (Nasdaq: CLLS) is developing allogeneic (“off-the-shelf”) CAR-T product candidates using gene editing of T-cells derived from healthy donors. Gene editing is performed using “transcription activator-like effector nuclease” (TALEN), a gene editing nuclease-based technology allowing very precise and targeted gene modifications to the CAR-T cells. Cellectis’ lead product is currently being developed for the treatment of CD19-expressing hematological malignancies such as acute lymphoblastic leukemia (ALL). Cellectis approach of using an allogeneic, frozen, “off-the-shelf” T-cell based medicinal product has the potential to overcome limitations experienced with autologous therapies, such as very high costs and difficult manufacturing logistics. At the American Society of Hematology (ASH) Meeting in December of 2018, Cellectis presented preliminary results from Phase I studies of UCART19. The data demonstrated an 82% complete remission rate in treated acute lymphoblastic leukemia patients.
Bellicum Pharmaceuticals (Nasdaq: BLCM) is developing two CAR-T candidate medicines: BPX-601 and BPX-603. BPX-601 is an autologous CAR-T product candidate engineered using Bellicum’s proprietary “activation switch technology”, which is designed to treat solid tumors expressing prostate stem cell antigen (PSCA). The use of Bellicum’s activation switch technology results in a higher number of CAR-T cells penetrating the tumor mass and attacking cancer cells. Bellicum’s CAR-Ts persist for a longer time in the tumor mass, which increases the efficacy of this cancer treatment. Furthermore, the activation switch technology triggers an anti-cancer immune response by the host, modulating the tumor microenvironment. All these features combined are designed to increase treatment potency relative to traditional CAR-T therapies. In a Phase I/II clinical trial, nine out of 17 (53%) PSCA-positive pancreatic cancer patients showed CAR-T cells persisting for more than three weeks in the tumor mass. In the trial, 62% of the evaluable patients (8/13) had stable disease and three patients showed tumor shrinkage of 10% to 24%.
Bellicum’s BPX-603 is a dual-switch CAR-T product containing both the “activation switch technology” and a “safety switch technology”. The safety switch technology programs CAR-T cells to commit suicide (apoptosis) if the treated cancer patient shows any symptoms of toxicity. The activation switch controls the potency and efficacy of the CAR-T, whereas the safety switch minimizes the treatment’s potential toxicity. Both switches are turned on by administering oral drugs to cancer patients. The activation switch is turned on by intake of the oral drug rimiducid, whereas the safety switch is turned on by rapamycin, another oral drug. Bellicum’s BPX-603 is the first controllable dual-switch CAR-T candidate medicine. It targets solid tumors that express the “human epidermal growth factor receptor 2 antigen” (HER2).
CRISPR Therapeutics (Nasdaq: CRSP) is developing CTX130 as an allogeneic CRISPR/Cas9 gene-edited CAR-T cell therapy targeting CD70 expressing cancers, including hematological (blood) and solid tumors. According to the medical literature, CRISPR/Cas9 gene editing is faster, cheaper and easier to use than competing gene editing systems such as “transcription activator-like effector nuclease” (TALEN), and zinc-finger nucleases (ZFNs).
Celyad SA (Nasdaq: CYAD) is developing a different type of chimera. Celyad’s CAR-T medicines consist of an engineered T lymphocyte with a TCR fused to the NKG2D receptor, which is normally found on the surface of natural killer (NK) cells. This chimera has also two heads: NKG2D receptor and TCR. It differs from traditional CAR-Ts on the replacement of the “antibody binding domain” by NKG2D receptor. Like T lymphocytes, natural killer cells have also the ability to destroy cancer cells. The advantage of using the NKG2D receptor over an antibody binding domain is that NKG2D binds to multiple tumor antigens, instead of only one antigen as it is the case for an antibody. Celyad believes that NKG2D chimeras will be more potent than traditional CAR-Ts for the treatment of cancer.
In summary, the consensus among academics and industry experts is that research and development in CAR-T area will intensify in coming years, fueled not only by the current success of Gilead and Novartis, but also by recent data with fourth generation CAR-T medicines. They expect more biotechnology companies jumping into the fray, as the industry copes with the challenges of treating solid tumors with anti-cancer cell therapies, and innovation in this area accelerates.
Sources:
“Chimeric Antigen Receptor (CAR) T Cell Therapy for Malignant Pleural Mesothelioma (MPM)”. Cancers 2017, 9(9) p115
“Fine and Predictable Tuning of TALEN Gene Editing Targeting for Improved T Cell Adoptive Immunotherapy”. Molecular Therapy: Nucleic Acids Vol. 9 December 15, 2017.
“Programming CAR-T cells to kill cancer”. Nature Biomedical Engineering 2018, Vol 2, June 2018, p377-391
Switching on the green light for chimeric antigen receptor T-cell therapy. Clinical & Translational Immunology 2019, Vol 8, e1046
“CAR-T with License to Kill Solid Tumors in Search of a Winning Strategy”. International Journal of Molecular Sciences 2019, Vol 20, p1903
“Chimeric-antigen receptor T (CAR-T) cell therapy for solid tumors: challenges and opportunities”. Oncotarget 2015, Vol 8(52), p90521-90531
“Two-Dimensional Regulation of CAR-T Cell Therapy with Orthogonal Switches”. Molecular Therapy - Oncolytics 2018 Dec 20;12:124-137
“Therapeutic potential of CRISPR/Cas9 gene editing in engineered T-cell therapy”. Cancer Medicine 2019, DOI: 10.1002/cam4.2257
NEWS Channel
Research - ACCO Brands Corporation (ACCO) - Risk Or Reward Is Favorable, 01/06/2020
Can Algorithmic Trading Continue to Expand?, 01/06/2020 Research - Scorpio Bulkers (SALT): Tanker Investment Helps Offset Weaker Dry Bulk Market, 01/03/2020 Research - Great Lakes Dredge & Dock (GLDD) - Yearend Awards Total $83 million - Large Potential Awards on Horizon, 01/02/2020 Research - Kratos Defense & Security (KTOS) - Well Positioned for 2020, 01/02/2020 How Investment Professionals are Preparing for the New Decade, 12/31/2019 Research - Energy Fuels (UUUU) - Is Relief for the Uranium Industry Imminent?, 12/30/2019 Tech stocks were big winners in 2019 - Where to invest money in 2020?, 12/30/2019 Research - Aurania Resources (ARU:CA) - Making the Most of a Mineral-Rich Project, 12/27/2019 Research - Onconova Therapeutics (ONTX) - Recent MDS data and what it means for Onconova, 12/27/2019 Cryptocurrency and the Howey Test: Are They Securities?, 12/26/2019 Can KLK7 be used to treat skin inflammation?, 12/26/2019 Happy Holidays, 12/24/2019 Space Force Will Require Emerging Technologies, Emerging Growth Companies in Various Sectors may Soar, 12/23/2019 Research - E.W. Scripps Company (SSP) - Why Is Scripps Among Our 2020 Favorites?, 12/23/2019 Research - Sierra Metals (SMTS) - SMTS Updates Yauricocha Mineral and Reserve Estimate, 12/23/2019 Are Dual-Class Stocks a Mistake for Investors?, 12/20/2019 Research - The McClatchy Company (MNI) - A Hopeful Sign For The Equity, 12/20/2019 Improving Economy with Production Cuts are Pushing Oil Prices Higher, 12/19/2019 Research - Coeur Mining (CDE) - Exploration Efforts to Increase in 2020; Focus on Resource Discovery and Conversion, 12/19/2019 Research - QuoteMedia (QMCI) - Among Our Candidates For Most Likely To Succeed in 2020, 12/19/2019 Research - One Stop Systems (OSS) - Price Decline Presents Favorable Risk/Reward Opportunity, 12/18/2019 Research - ProMis Neuroscience (PMN:CA) - What Does Biogen’s Progress Mean for ProMIS?, 12/18/2019 Should the SEC Relax Requirements for Accredited Investors? , 12/17/2019 Putting the “Supplemental” Back into Non-GAAP Disclosures , 12/16/2019 Aramco Goes Public in the Same Week Chevron Announces a Large Write Down, 12/16/2019 Research - DLH Holdings Corp (DLHC): Well Positioned to Capitalize on Government Services Trends, 12/13/2019 Research - Energy Services of America (ESOA) - Solid Finish to Fiscal Year 2019 and Special Dividend Announced, 12/13/2019 Red-hot Biotech Stocks Boosting Small Cap Index, 12/13/2019 Research - DLH (DLHC): Another Solid Quarter with Revenue Topping Expectations, 12/12/2019 Finding a Cure for AIDS Part II (Dec. 2019), 12/12/2019 Research - Energy Services of America (ESOA) - Launching Coverage. Looking for Solid Finish to Fiscal Year., 12/11/2019 Research - Salem Media (SALM) - Why The Dividend Cut Should Help The Stock, 12/11/2019 Does Santa’s Early Arrival Mean Retailers will have a Merry Christmas?, 12/11/2019 Research - Coeur Mining (CDE): Increasing 2020 Estimates; Maintaining Outperform Rating, 12/10/2019 Research - 1-800-Flowers.com (FLWS): Flowers At A Discount, 12/10/2019 Research - Akazoo (SONG): Music To Our Ears, 12/10/2019 Research - Great Lakes Dredge & Dock (GLDD): Renewed Confidence in Dredging Market Outlook, 12/10/2019 Should Online Retailers Open Neighborhood Shops?, 12/09/2019 Should Government Limit the Export of Fossil Fuels?, 12/06/2019 Research - Comtech (CMTL) - Strong Q1; Can The Momentum Be Maintained?, 12/05/2019 Research - QuoteMedia (QMCI) - What Investors Are Looking For, 12/05/2019 New Era of Gene Therapy , 12/04/2019 Can Modern Monetary Theory Work?, 12/04/2019 Research - Harte-Hanks (HHS) - New Leadership For A New Phase?, 12/03/2019 Research - Aurania Resources (ARU:CA) - On the Road to Finding the Lost Cities?, 12/02/2019 Research - Great Panther Mining Limited (GPL) - GPL Cuts 2019 Production Guidance Again; Lowering Rating to Market Perform, 12/02/2019 Today's Feature, 12/01/2019 Research - Akazoo (SONG) - Creating A New Vibe On Messaging, 11/27/2019 Research - Comtech (CMTL) - Satellite Ground Equipment Acquisition, 11/27/2019 Is Tesla’s Cybertruck a Turkey?, 11/27/2019 The “Pilgrims” of Today, 11/27/2019 Research - Dyadic (DYAI) - Step Closer to Generating Human-like Proteins with C1 Platform, 11/26/2019 Research - Euroseas (ESEA) - 3Q2019 Results In Line. Another Acquisition Adds Scale, 11/26/2019 Research - Information Services (III) - RPA Market Continues to Attract Investors, 11/26/2019 Should Investors be Wary of the Companies Raising Dividends?, 11/25/2019 Is Company Sponsored Research the Future for Small-Cap Stock Investors?, 11/25/2019 Research - Aurania Resources (ARU:CA) - Drilling at Yawi is Off to a Good Start, 11/22/2019 Research - Onconova Therapeutics (ONTX) - What do recent deals mean for Onconova?, 11/22/2019 Research - Great Lakes Dredge & Dock (GLDD) - Investor Meetings Renew Confidence, 11/21/2019 Have Active Managers Received a Bum Rap?, 11/21/2019 Research - Tribune Publishing (TPCO) - What Does A Change In Its Largest Shareholder Mean?, 11/20/2019 The pros and cons of media consolidation, 11/20/2019 Why are basic material industries suffering despite government help?, 11/19/2019 Research - EuroDry (EDRY) Solid Quarter and Balanced Contracting Tempers Volatility, 11/18/2019 Research - ProMIS Neurosciences (PMN:CA) - Progress Made in Q3 Bodes Well for ProMIS' Prospects, 11/15/2019 Research - Pyxis Tankers (PXS) - Solid Improvement Likely Extends Into Next Year, 11/15/2019 Research - Sierra Metals (SMTS) - Higher EBITDA and Operating Cash Flows Driven by Strong Q3 Production, 11/15/2019 Research - electroCore (ECOR) - Q3 2019: Revising Outlook After Slow Quarter, 11/15/2019 Research - QuoteMedia (QMCI) - Not Likely To Move The Needle, 11/14/2019 Research - The McClatchy Company (MNI) - Lots Of Balls In The Air, 11/14/2019 In an Increasingly Mobile Society, Will Cryptocurrencies Gain More Acceptance? , 11/14/2019 Research - Dyadic (DYAI) - Q3 2019: Continuing Expansion of C1 Technology Applications, 11/14/2019 Research - Endeavour Silver (EXK) - Will El Curso Play a Role in Guanacevi's Turnaround?, 11/13/2019 Research - Genie Energy (GNE) - Boring quarter welcomed after rough 2Q, 11/13/2019 Research - Harte-Hanks (HHS) - Ahead Of Its Turnaround Plan, 11/13/2019 Research - Salem Media (SALM) - Addressing The Elephant In The Room, 11/13/2019
The Channelchek Equity Research College Challenge on the NASDAQ Tower, 11/13/2019 Does the recent RAS inhibitor data show that we can effectively treat RAS-related cancers?, 11/12/2019 Research - Cumulus Media (CMLS) - Building Value Through Aggressive Debt Reduction, 11/12/2019 Research - Pangaea Logistics Solutions (PANL) - Unique Business Model Delivers Solid Results, 11/11/2019 Research - Information Services Group Inc. (III) - Additional 3Q19 Comments; Updated Projections, 11/11/2019 Research - E.W. Scripps Company (SSP) - What Is At The Core Of Q3 Results?, 11/11/2019 Research - Trovagene (TROV) - Q3 2019 Results: Trovagene Continues Progressing, 11/11/2019 Research - Eagle Bulk Shipping (EGLE) - Stock Price Weakness Spells Opportunity, 11/08/2019 Research - Entravision Communications Corporation (EVC) - What It Can Do To Change The Narrative?, 11/08/2019 Research - Gray Television (GTN) - Does Q3 Political Indicate a Windfall for 2020, 11/08/2019 Research - One Stop Systems Inc. (OSS) - Strong 3Q19 Sets Stage for Excellent Full Year 2019, 11/08/2019 Research - Tribune Publishing Company (TPCO) - Why This Quarter Reflects The Quality Of Its Cash Flow, 11/08/2019 Research - Genco Shipping (GNK) - Improving Financials and Asset Sales Trigger Special and Regular Dividends, 11/07/2019 Research - Information Services Group (III) - Mixed Third Quarter Results, But Record Adjusted EBITDA and Strong Cash Generation, 11/07/2019 Research - Kelly Services Inc. (KELYA) - What Was Behind the Disappointing 3Q19 Results?, 11/07/2019 Research - Seanergy (SHIP) - 3Q2019 Shortfall Masks Improving Operating Results, 11/07/2019 Research -Coeur Mining (CDE): Q3 Results Better Than Expected; Increasing Estimates, 11/06/2019 Research - Endeavour Silver (EXK): Third Quarter In Line With Our Expectations; Lowering 2020 Estimates, 11/06/2019 Research - Great Lakes Dredge & Dock (GLDD): Backlog rebounded and set up for strong finish to year, 11/06/2019 Research - Kratos Defense & Security (KTOS): Another Solid Quarter But Will Continuing Resolution Hit The Pause Button?, 11/06/2019 Research - Townsquare Media (TSQ): Scores Another Good Quarter , 11/06/2019 Research - Vectrus (VEC): Can Outperformance Continue?, 11/06/2019 Are Strong Earnings a Sign that Economic Concerns are Unwarranted? , 11/05/2019 Taking Stock of Index Funds, 11/04/2019 Research - Energy Fuels (UUUU) - No Big Surprises , 11/04/2019 Research- Great Panther Mining (GPL) - Q3 Falls Short on EPS but Exceeds on EBITDA, 11/01/2019 Research - Orion Group Holdings (ORN) - On the Right Track. Moving Up Estimates., 11/01/2019 Research - 1-800-Flowers.com (FLWS) - A Surprisingly Good Harvest, 11/01/2019 Research - ACCO Brands (ACCO) - Post 3Q19 Conference Call Notes, 10/31/2019 Research - ORION Group Holdings - Transition Continues with Another Solid Quarter., 10/31/2019 Research - ACCO Brands (ACCO) - Record 3Q19 Cash Flow; But Top and Bottom Lines Weaker than Expected, 10/30/2019 Research - Comtech (CMTL) - A Troposcatter Win for Comtech?, 10/30/2019 Waning Stock Buybacks: Should Investors be Worried? , 10/29/2019 Sins of Omission , 10/29/2019 Research - Genco Shipping (GNK) - Adjusting Estimates for Updated Scrubber Program Progress, 10/28/2019 Research - Onconova Therapeutics (ONTX) - Completion of Enrollment is Pushed Back but Data Readout is on Track, 10/25/2019 Was the US Right in Removing Troops from Syria?, 10/25/2019 Industry Report - Noble Capital Markets Biotechnology Industry Overview, 10/25/2019 Research - ProMIS Neurosciences (PMN:CA) - Is ProMIS’ Alzheimer’s Antibody Better Than Biogen’s?, 10/24/2019 Research - Scorpio Bulkers (SALT) - Making A Good Move With Special Dividend, 10/24/2019 Research - Aurania Resources (ARU:CA) - Full Speed Ahead, 10/23/2019 Research - Genco Shipping (GNK) - 2H2019 Recovery Intact Despite Recent Weakness, 10/23/2019 Looking for Money Growing on Trees? Try Timber., 10/22/2019 Is Fracking Safe?, 10/22/2019 Brant Pinvidic, Host of IPO Podcast Series, on the Channelchek College Research Report Challenge, 10/21/2019 Can Biosimilars Finally Be Successful in the US?, 10/18/2019 Research - Seanergy (SHIP) - Positive Impact from Dry Bulk Market Firmness, 10/17/2019 Research - Great Panther Mining Limited (GPL) - GPL Cuts 2019 Production Guidance; Lowering Estimates and Price Target, 10/17/2019 Research - Sierra Metals (SMTS) - Third Quarter Production Above Expectations; Raising Estimates, 10/17/2019 Research - Avino Silver & Gold (ASM) - Avino Reports Third Quarter 2019 Production; Dropping Research Coverage, 10/17/2019 Research Initiation - Akazoo (SONG) - Getting The Company For A Song, 10/16/2019 Research - Scorpio Bulkers (SALT) - Dry Bulk Market Firmer, But Fine-Tuning 2H2019 Estimates, 10/16/2019 Research - DLH Holdings Corp. (DLHC) - Announces Preliminary Results for FY19, 10/16/2019 Research - Coeur Mining (CDE) - Laying the Groundwork for Improved Performance in 2020, 10/14/2019 Show Me the Money: Should College Athletes Play for Pay?, 10/14/2019 Going to the Movies? A Theater or Stream?, 10/11/2019 Are Planned Power Outages Worth the Cost? , 10/11/2019 Research - Endeavour Silver (EXK) - Still In Turnaround Mode; Visible Path for Improvement, 10/10/2019 Industry Report - Media - Is The Sell-Off Over?, 10/10/2019 Developing a Research Driven Approach: an Investment Bank’s Perspective Webinar, 10/10/2019 Investing in Microcap Biotech Stocks, Risks and Rewards, 10/09/2019 How Long Will U.S. Petrochemical Producers Maintain Their Global Advantage?, 10/09/2019
NetworkNewsBreaks – Genprex, Inc. (NASDAQ: GNPX) Announces Plans to Present at Inaugural MicroCap Rodeo Investor Conference, 10/09/2019 Ducommun Incorporated Acquires Nobles Worldwide, 10/09/2019 Industry Report - Energy - Summer's End Brings No Relief For Energy Stocks, 10/08/2019 Who Is to Blame for the Weak Manufacturing Number and the Market Crash? , 10/08/2019 Industry Report - Metals & Mining Third Quarter Review and Outlook, 10/07/2019 Research - Eagle Bulk Shipping (EGLE) - Scrubber Program Change Impacts Estimates, But Outlook Remains Solid, 10/07/2019 Research - QuoteMedia, Inc. (QMCI) - Could A Bear Market Help This Company?, 10/04/2019 What’s Going on with the IPO Market?, 10/04/2019
IPO Podcast - Vanessa Van Edwards, 10/04/2019 Research - Great Panther Mining Limited (GPL) - Raising Estimates Based on Improving Outlook, 10/03/2019 Research - Orion Group Holdings (ORN) - Two Marine Awards Help 2020 Outlook, 10/03/2019 Research - Great Lakes Dredge & Dock (GLDD) - Total 3Q2019 Awards of $319 million Above Expectations., 10/03/2019 Research - Great Lakes Dredge & Dock (GLDD) - Two New Jobs - 3Q2019 Awards Likely Above $265 million, 10/02/2019 Research - electroCore (ECOR) - What Do Recent Developments Mean For electroCore?, 10/02/2019 Research - Kratos Defense & Security - Risk-Reward Turns Favorable. Upgrading Rating, 10/02/2019 Research - Euroseas (ESEA) - One Good Contract But Rest of the Fleet Not Following...Yet., 10/01/2019 Research - Sierra Metals (SMTS) - Looking Ahead to 2020, 10/01/2019 Research - Trovagene (TROV) - Number of Patients with a Complete Response Increases in AML Study, 10/01/2019 Positive Data from Trovagene Phase 1b_2 Study of Onvansertib Featured in Oral Presentation at European Society for Medical Oncology (ESMO) Conference, 09/30/2019 IPO Podcast Series: Vanessa Van Edwards, 09/30/2019 Research - Great Lakes Dredge & Dock (GLDD) - Backlog Rebound, 09/27/2019 Research - Kelly Services (KELYA) - What's Next?, 09/27/2019 Research - TherapeuticsMD (TXMD) - On Track for Annovera Soft Launch, 09/27/2019 NetworkNewsAudio – Genprex Inc. (NASDAQ: GNPX) Building Encouraging New Breast Cancer Treatment Options, 09/27/2019 Research - Energy Fuels (UUUU) - Relief on the Horizon?, 09/26/2019 Research - EuroDry (EDRY) - Moving Estimates Higher, 09/26/2019 Research - Comtech (CMTL) - Raising PT, 09/25/2019 Smallcap Rally: Russel 2000 Trumps S&P 500 in September , 09/25/2019 Will New 2020 Climate Change Policies Affect the Market? , 09/25/2019 Noble Capital Markets Launches Small and Microcap Equity Research Contest, 09/25/2019 Research - Scorpio Bulkers (SALT) - Will Dry Bulk Market Remain Firm?, 09/24/2019 Cut to the Chase: The Reality of Rate Cuts, 09/24/2019 Boeing 737 MAX: What’s Taking So Long?, 09/24/2019 Research - Endeavor Silver (EXK) - Rating Upgrade, 09/23/2019 Research - Aurania Resources (ARU.V) - Closed Private Placement, 09/23/2019 Research - Kratos (KTOS) - Momentum in Unmanned Systems, 09/23/2019 Silver Still has a Place on the Winners’ Podium, 09/23/2019 Noble Capital Markets Supports Bahamas Relief Fund Through its NobleCon Investor Conference, 09/23/2019 Can Smallcap Funds Help Cap Index Overlap in Your Portfolio? , 09/20/2019 Is the US Accelerating toward Becoming the World’s Energy Capital? , 09/20/2019 Research - Orion (ORN) Construction Awards Bolster Outlook, 09/19/2019 Attack on Saudi Refinery: What Does it Mean for You, the Investor?, 09/19/2019 Investing in Cannabis: Should You Go Green? , 09/19/2019 Mortgage Rates Jump, 09/19/2019 Voice of Blockchain to Offer Insights for all Members of the Blockchain Ecosystem, 09/19/2019 Offshore Wind Power Blows into the Energy Market, 09/18/2019 Directed Energy Weapons: Star Wars Redux?, 09/18/2019 Scotiabank supports young Canadians with a $500,000 donation to the Terry Fox PROFYLE program, 09/18/2019 How Will the Authorization of AB5 Impact Gig Economies?, 09/17/2019 Will the Market Surpass All-Time Highs? , 09/17/2019 Industry Report - Minerals - Insights from the Precious Metals Summit, 09/16/2019 Onconova Therapeutics Announces Presentation on Rigosertib at the RAS-Targeted Drug Discovery Summit, 09/16/2019 ProMIS Neurosciences Executive Chairman Eugene Williams to Speak on Panel at Fall Investor Summit, 09/16/2019 NNW News - OnDeck Survey: Economy is Top Concern for Small Businesses Ahead of 2020 Election, 09/13/2019 Will the Oil Slowdown Provoke a Renewable Energy Takeover?, 09/13/2019 NetworkNewsAudio – Genprex Inc. (NASDAQ: GNPX) Developing Revolutionary Gene Therapies to Fight Cancer, 09/13/2019 Chek-in with Mike Kupinski and the CFO of E.W. Scripps, Lisa Knutson., 09/13/2019 Research - Great Lakes Dredge & Dock (GLDD), 09/12/2019 Taking the FDA shortcut, 09/12/2019 Industry Report - Biotechnology - Key Catalysts for Oncology Companies, 09/12/2019 Industry Report - Biotechnology - Success of Cancer Vaccines Approaching?, 09/12/2019 Are Nanocap Stocks a Beneficial Addition to Your Portfolio?, 09/11/2019 Hurricanes Do More Damage than What’s on the Surface , 09/11/2019 Independent Researchers Find Genprex's TUSC2 Prevents Tumor Growth in Triple-Negative Breast Cancer, 09/11/2019 Research - Eagle Bulk Shipping (EGLE) - Signaling a Recovery, 09/10/2019 How Can Innovations in Transportation and Logistics Provide Value to Investors?, 09/10/2019 Cyclical Economic Shifts: Industrial Companies Could Feel the Effects, 09/10/2019 Will the Longest Economic Expansion in History Continue? , 09/09/2019 Can Investing in Natural Resources Provide Future Value?, 09/06/2019 Will Renewable Energy be the Downfall of Fossil Fuels? , 09/06/2019 Are the Trade Troubles Coming to an End?, 09/05/2019 Prescription Drug Pricing: How Would Limited Government Intervention Change the Landscape? , 09/05/2019 Dyadic to Present at Janney Healthcare Conference, 09/04/2019 Everything from A-to-Z: There are Consumer Cyclical Stocks for Everyone , 09/04/2019 Utility Stocks May Offer Low-Risk Investment Potential, 09/04/2019 Research - QuoteMedia (QMCI) - A Look Ahead, 09/03/2019 Genprex Provides Forward Looking Guidance and Updates on Corporate Activities, Publishes New Corporate Deck, 09/03/2019 ProMIS Neurosciences to Present at HC Wainwright Investment Conference, 09/03/2019 Treasure hunt? Let’s Talk Silver, 09/03/2019 Research - Aurania Resources (ARU:CA) - Updating Estimates, 08/30/2019 Will the Slowing in Quarter 3 Affect Microcap Stocks? , 08/30/2019 Worth the Risk? An Overview of Investing in Small & Microcap Stocks. , 08/30/2019 How can Blockchain Help Accelerate the Agriculture Industry?, 08/30/2019 Are Shipping Stocks Shipwrecked by the U.S. and China Disputes?, 08/29/2019 How Will Rising Trade Tensions Impact the Aerospace Industry? , 08/29/2019 IPO Podcast - Rob Lowe, 08/29/2019 Research - One Stop Systems (OSS) - ATM Completed, 08/28/2019 Research - E.W. Scripps (SSP) - Differentiated From Its Peers, 08/28/2019 Research - Trovagene (TROV) - Progressing Prostate Cancer Data in Small Number of Patients, 08/27/2019 Pharma Mergers and Acquisitions: Who’s Really Winning Here?, 08/27/2019 Will the Uncertain Economy Boost Mining Stocks? , 08/27/2019 NNW News - Entrepreneurs Tips To Take Gig Work To The Next Level, 08/27/2019 NNW News - Genprex Inc. (GNPX) Making Headway in Clinical Program Expansion, Company Growth, 08/27/2019 Trovagene Presents Positive Clinical Data from Ongoing Phase 2 Study of Onvansertib in Metastatic Castration-Resistant Prostate Cancer (mCRPC), 08/26/2019 What If Yields Turn Negative?, 08/26/2019 Research - Aurania Resources (ARU.V) - A Growing Number of Targets, 08/23/2019 Research - 1-800-Flowers.com (FLWS) - Why this quarter stands out., 08/23/2019 Will Iran Continue to Grow Their Nuclear Program? , 08/22/2019 Aurania Refines Its Newly Discovered Apai Gold-Silver Target in Southeastern Ecuador, 08/22/2019 Reserach - Great Lakes Dredge & Dock (GLDD) - Backlog Rebound Expected, 08/21/2019 The inverted yield curve: what does this really indicate? , 08/21/2019 Can Germany Survive the Trade War?, 08/21/2019 Research - Tribune Publishing (TPCO) - Content to Drive Value, 08/20/2019 Microsoft Acquires PromoteIQ in an attempt to compete with Amazon, 08/20/2019 Research - Euroseas (ESEA) -Quarterly Results Stabilizing, 08/19/2019 Can Blockchain Revolutionize the Banking Industry?, 08/19/2019 Growing Industry: What Should We Look For?, 08/19/2019 Research - EuroDry (EDRY) - Improving Environment, 08/16/2019 Research - Sierra Metals (SMTS) - Positioned for Improvement, 08/16/2019 Research - Onconova Therapeutics (ONTX) - Inflection Points Ahead, 08/15/2019 Too Busy to Shop? The Rise of Meal Kit Delivery Services, 08/15/2019 Will owning an Electric Vehicle finally be convenient? , 08/15/2019 Can consumers positively impact the current economic outlook?, 08/15/2019 Research - Dyadic International (DYAI) - Data and Additional Partnerships to Expand Further Value, 08/14/2019 Research - electroCore (ECOR) - Soothing Investors' Migraine a Bit?, 08/14/2019 Research - Pangaea Logistics (PANL) - Lower 2Q2019 Shipping Days, But Rebound Ahead, 08/14/2019 Research - ProMIS Neurosciences (PMN:CA) - Strengthening Drug Portfolio by Adding Novel Alzheimer's Antibodies, 08/14/2019 Research - QuoteMedia, Inc. (QMCI) - Second Quarter Results Indicate Favorable Momentum, 08/14/2019 Research - Harte Hanks (HHS) - Substantial Progress Made, 08/13/2019 Research - Pyxis (PXS) - On Track for Rebound, 08/13/2019 Research - E.W. Scripps (SSP) - A Surprising Reaction , 08/13/2019 Research - Salem Media (SALM) - Hitting Fast Forward, 08/13/2019 Can Hong Kong Retain Its Autonomy?, 08/13/2019 FEATURE: Research | NobleCon | Podcast, 08/12/2019 Research - Trovagene (TROV) - Inflection Points Later this Year, 08/12/2019 Research - Endeavor Silver (EXK) - Setting the Stage for Growth, 08/12/2019 China currency devaluation: Who is this helping?, 08/12/2019 Research - Genco Shipping (GNK) - A Tough Quarter But Rebound Ahead, 08/09/2019 Research - Avino Silver & Gold (ASM) - Entering the Second Half with Strong Liquidity and Leverage to Higher Commodity Price, 08/09/2019 Research - Coeur Mining (CDE) - Momentum Building in the Second Half?, 08/09/2019 Research - One Stop Systems (OSS) - A Solid 2Q Rebound Sets Up the Second Half of 2019, 08/09/2019 Research - Cumulus Media (CMLS) - Favorable Cash Flow Picture Provides Confidence In Debt Reduction Target, 08/09/2019 Research - Harte-Hanks (HHS) - With Progress Comes Increased Confidence In Its Turnaround, 08/09/2019 Research - The McClatchy Company (MNI) - Significant Progress Toward Maintaining Cash Flow, 08/09/2019 Research - ACCO Brands (ACCO) - New $100 Million Share Repurchase Authorization Continues Capital Return Theme, 08/08/2019 Research - IEC Electronics (IEC) - Will they really be able to convert this backlog efficiently?, 08/08/2019 Research - Orion Group Holdings (ORN) - A Construction Award Bolsters Robust Outlook, 08/08/2019 Research - Kelly Services (KELYA) - Will the Second Half of 2019 Be Better than the First Half?, 08/08/2019 Research - TherapeuticsMD (TXMD) - Promising Quarter Signaling to a Positive 2H 2019, 08/08/2019 Research - Tribune Publishing (TPCO) - Another Beat And Raise; Will Investors Take Notice?, 08/08/2019 Markets see a slight calm: how long will this last?, 08/08/2019 Research - Gray Television (GTN) - Advertising Appears Resilient, 08/08/2019 IPO Podcast - Patrick Drake, 08/08/2019 Research - DLH Corporation (DLHC) - 3Q Post Call Analysis, 08/07/2019 Research - Seanergy Maritime (SHIP) - Solid Quarter and Strong Start to 2H2019, 08/07/2019 Industry Report - Biotechnology Overview, 08/07/2019 Research - Vectrus (VEC) - Today's Investments Will Pay Off Tomorrow, 08/07/2019 Research - Entravision Communications (EVC) - Will It Make Headway Fixing Digital?, 08/07/2019 Research - Townsquare Media (TSQ) - Hitting a Nice Stride, 08/07/2019 Bull or bear dollar in the near future?, 08/07/2019 Research - Gray Television (GTN) - A Solid Quarter, 08/07/2019 Research - ACCO Brands (ACCO) - What Will New Acquisition Mean?, 08/06/2019 Research - DLH Holdings Corp (DLHC) - What Do 3Q19 Results Tell Us About the Combined Company?, 08/06/2019 Research - Information Services (III) - Will Back Half of Year Be Better Than First Half?, 08/06/2019 Research - Energy Fuels (UUUU) - Looking Ahead to Working Group Recommendations Expected in October, 08/06/2019 Research - 1-800-Flowers.com (FLWS) - The Latest Acquisition Is The Berries, 08/06/2019 Research - Gannett Company (GCI) - Did Gannett Get The Most It Could?, 08/06/2019 Research - Genie Energy (GNE) - Earnings Miss Causes Decline in Stock, 08/06/2019 Research - Ducommun (DCO) - Can Momentum in Commercial Aerospace Outlast 737 MAX Headwinds?, 08/06/2019 Is Solar Energy the Way of the Future?, 08/05/2019 What’s the deal with CBD?, 08/05/2019 How far will plant-based foods go?, 08/02/2019 What Are the Dangers of the Capital One Data Breach? , 08/02/2019 Research - Aurania Resources (ARU.V) - Drilling Activity Expected to Accelerate in the Second Half, 08/01/2019 Research - Prize Mining Corporation (PRZ.V) - Taking Steps to Better Position the Company in the Eyes of Investors, 08/01/2019 Research - ACCO Brands (ACCO) - A Deeper Dive Into Record 2Q19 Results, 08/01/2019 Research - Albany International Corp. (AIN) - Woah... Why were aerospace margins so strong this quarter?, 08/01/2019 Research - Great Lakes Dredge & Dock (GLDD) - Fourth Strong Quarter In A Row. Backlog Rebound Ahead., 08/01/2019 Research - Orion Group Holdings (ORN) - Rebound Appears Underway Sooner Than Expected, 08/01/2019 Research - Kratos Defense & Security (KTOS) - Will the Outperformance Continue?, 08/01/2019 Research - ACCO Brands (ACCO) - Record 2Q Results; What's In-store for the Rest of the Year?, 07/31/2019 CAR-T Cancer Treatment: Part 3, When Breakthroughs Converge, 07/31/2019 U.S. second quarter labor costs increases by the smallest amount in 1 ½ years, 07/31/2019 IPO Podcast - Kathy Ireland, 07/31/2019 Research - Eagle Bulk Shipping (EGLE) - A Tough Quarter But Set Up for 2H2018 Rebound, 07/30/2019 Moderate Increase in U.S. Prices and Consumer Spending, 07/30/2019 Tensions Rise on First Federal Reserve Rate Cut in a Decade, 07/30/2019 Research - Orion Group Holdings (ORN) - Transition Quarter to Strong Second Half Rebound, 07/29/2019 Research - Eurodry (EDRY) - Positive Impact from Preferred Changes and Recent Dry Bulk Market Rebound., 07/29/2019 Research - Great Panther Mining Limited (GPL) - Turning the Corner, 07/29/2019 Is The IRS Cracking Down On Cryptocurrency? , 07/29/2019 Research - Kelly Services (KELYA) - Initiating Coverage; A Leading Staffing Company Poised for Additional Growth, 07/29/2019 Research - Eagle Bulk Shipping (EGLE) - Convert Debt Funds Another Acquisition, Pressures Stock Price, 07/26/2019 Research - Onconova Therapeutics - Initiation of Coverage, 07/25/2019 eSports- The Next Big Thing?, 07/25/2019 Can Micro-Mobility Solve Last-mile Transportation Issues?, 07/24/2019 Regulatory Overstep? How will MiFID II impact financial markets?, 07/24/2019 IPO Podcast - Christie Hefner, 07/24/2019 IPO Podcast Series: Rob Lowe, 07/24/2019 IPO Podcast Series-1, 07/24/2019 IPO Podcast Series, 07/24/2019 Research - ProMIS Neurosciences (PMN:CA) - Amid Skepticism, Light Will Emerge in Alzheimer's Area, 07/23/2019 Research - Scorpio Bulkers (SALT) - Worst Has Passed and Rebound Underway, 07/23/2019 Is the transportation sector signaling the next recession?, 07/23/2019 Research - Seanergy Maritime (SHIP) - Cape Market Moving Sharply Higher, SHIP Should Move Up Too, 07/22/2019 Cryptocurrency Controversy? Facebook Reveals Libra. , 07/22/2019 Research - Avino Silver & Gold (ASM) - What is the Expected Impact of Phasing Out San Gonzalo?, 07/19/2019 IPO Podcast Series: King Bach, 07/19/2019 Research - Orion Group Holdings (ORN) - Another Project Award Boosts Record Backlog and Reinforces Positive Outlook, 07/18/2019 Industry Report - Media - Is It Too Early To Bet On Political Advertising?, 07/18/2019 Deepfakes: Has Artificial Intelligence Gone Too Far?, 07/18/2019 Media Quarterly Review Q2 2019, 07/18/2019 Research - Sierra Metals (SMTS) - Will the Momentum Continue?, 07/17/2019 What’s Up Next for Blockchain?, 07/16/2019 Metals And Mining Quarterly Review Q2 2019, 07/16/2019 Energy Quarterly Review Q2 2019, 07/16/2019 Research - Aurania Resources (ARU.V) - Employing Big Data in the Rainforests of Ecuador, 07/15/2019 Research - Coeur Mining (CDE) - Will Recent Strength in Gold Prices Benefit Second Half Performance?, 07/15/2019 Research - Energy Fuels (UUUU) - Section 232 Petition Prompts Working Group for More Study, 07/15/2019 The Controversial Question: Would You Answer It?, 07/15/2019 Can These Tech Unicorn Companies Prove Their Worth?, 07/12/2019 Research - Endeavour Silver (EXK) - A Work In Progress, 07/11/2019 Research - Great Panther Mining Limited (GPL) - When Will the Valuation Reflect an Improving Growth Outlook?, 07/11/2019 Research - QuoteMedia Inc. - Initiation Report, 07/11/2019 News - Are Driverless Vehicles Being Over-Hyped?, 07/10/2019 Research - DLH Holdings (DLHC) - An Early Look at the Combined DLH and Social & Scientific Systems, 07/10/2019 Research - Trovagene (TROV) - What does Colorectal Cancer Trial Add?, 07/10/2019 News - Mission (Im)possible: (Un)druggable RAS?, 07/09/2019 Research - Vectrus (VEC) - What does Advantor Systems add to Vectrus?, 07/09/2019 Research - One Stop Systems (OSS) - What Impact Will the $60 Million OEM Agreement Have?, 07/09/2019 Research - Dyadic (DYAI) - VTT to Continue Validation of C1 Platform in Bioproduction., 07/08/2019 Fed Rate Cut: Who Does it Affect?, 07/08/2019 Exploring a New Frontier: 5G Networking, 07/05/2019 IPO Podcast Series: Kathy Ireland, 07/04/2019 Research - Entravision Communications (EVC) - Sheds Light on the Matter, 07/03/2019 Industry Report - Minerals - Are Mining Stocks Poised for a Better Second Half?, 07/03/2019 Research - Vectrus (VEC) - Named to Another Contract; Massaging Estimate, 07/02/2019 Industry Report - Energy - The storage numbers tell it all, 07/02/2019 Big Tech Headed For A Big Breakup? FAANG, 07/02/2019 Research - Seanergy Maritime (SHIP) - Class C Warrants Expanding Share Count, 07/01/2019 Peace At Last? U.S.-China Announce Trade Truce, 07/01/2019 Research - Prize Mining (PRZ) - Charting a Course for Kena Gold Property, 06/28/2019 IPO Podcast Series: Christie Hefner, 06/27/2019 News - Wind Energy: Is it efficient enough?, 06/25/2019 Research - Great Lakes Dredge (GLDD) - More Awards Announced; 2H3019 Backlog Expected, 06/25/2019 Research - Euroseas (ESEA) - Acquisition and Financing Activity Are Positives, 06/24/2019 News - CFA, CFP, CPA, CAIA, ChFC, CIPM, OMG when will it end?, 06/21/2019 FEATURE: NobleCon 16 | Tanker Attack | Research | Podcast, 06/20/2019 Research - Great Lakes Dredge (GLDD) - Awards Boost Confidence, 06/20/2019 News - A Chimera for the Treatment of Cancer (Part 2), 06/20/2019 Research - Endeavour Silver (EXK) - Signs of an Improving Outlook?, 06/19/2019 Research - TherapeuticsMD (TXMD) - What Investors are Missing, 06/19/2019 Research - Upgrading the Shares - High Risk but High Upside Potential, 06/17/2019 News - What will the Persian Gulf attack mean for oil prices?, 06/17/2019 Research - Aurania Resources - Lessons from Crunchy Hill, 06/14/2019 Noble Capital Markets’ sixteenth annual investor conference, 06/14/2019 Research - Cumulus Media (CMLS) - Debt Recovery Should Help Stock, 06/13/2019 Research - DLH Holdings Corp. (DLHC) - Potential Transformative Factors, 06/13/2019 Research - KeyW Holding (KEYW) - Jacobs Tender Offer Completed, 06/13/2019 Research - Townsquare Media (TSQ) - Why is the stock below its peers?, 06/11/2019 Research - electroCore (ECOR) - ECOR Braves Choppy Waters, 06/11/2019 Research - Comtech (CMTL) - Can the Current Upswing be Maintained?, 06/07/2019 News - A Chimera Becomes a Novel Cancer Treatment (Part 1), 06/06/2019 Research - Comtech (CMTL) - Q3 Delivers Record Backlog, 06/06/2019 Research - electroCore (ECOR) - Departing Founder and Chief Science and Strategy Officer, 06/05/2019 Research - Kratos (KTOS) - Price Appreciation Pushes to Market Perform, 06/05/2019 News - Tariffs Make a Run for the Border, 06/04/2019 Research - Aurania Resources (ARU.V) - Copper Exploration Yields Encouraging Results, 05/31/2019 Research - electroCore (ECOR) - Plans to Remove Headwinds, 05/31/2019 News - The Great Debate: Active or Passive Management?, 05/30/2019 Research - Euroseas (ESEA) - Price Target Revision, 05/30/2019 News - Will electric cars stall the demand for oil?, 05/28/2019 Research - EuroDry (EDRY) - Increasing EBITDA Estimate, 05/28/2019 Research - Pyxis Tankers (PXS) - Still Looking for a Recovery, 05/24/2019 Research - Trovagene (TROV) - Agreement with Nektar Therapeutics, 05/24/2019 Research - McClatchy (MNI) - Raising Our Rating, 05/23/2019 News - Videogames: The Next Professional Sport, 05/22/2019 Research - Pangea Logistics (PANL) - New Dividend, 05/21/2019 Research - Great Panther Silver (GPL) - Reports first quarter loss, 05/17/2019 Research - Pangaea Logistics (PANL) - Another Solid Quarter; Consistent Business Model, 05/17/2019 Research - One Stop Systems (OSS) - Files $100 Million Shelf Registration, 05/17/2019 Research - Entravision (EVC) - Investor Call Highlights, 05/17/2019 Research - electroCore (ECOR) - Stock price doesn't reflect the value of gammaCore, 05/17/2019 Research - electroCore (ECOR) - First quarter 2019 results are below expectations, 05/16/2019 Research - Entravision (EVC) - First quarter 2019 update, 05/16/2019 Research - Sierra Metals (SMTS) - Reports first quarter loss, 05/15/2019 Research - ProMIS Neurosciences (PMN:CA) - First quarter 2019 progression, 05/15/2019 Research - Genco Shipping (GNK) - Adjusting estimates; weak market environment, 05/14/2019 Research - E.W. Scripps (SSP) - Lowering price target, 05/14/2019 Research - Avino Silver & Gold (ASM) - First quarter results, updating estimates, 05/13/2019 News - Will Green Dreams Turn Into Coal’s Nightmare?, 05/13/2019 Research - Information Services (III) - First quarter 2019 results, 05/13/2019 Research - Ducommun (DCO) - Rating changed to Market Perform, 05/13/2019 Research - Energy Fuels (UUUU) - Weaker than expected first quarter results, 05/13/2019 Research - Seanergy (SHIP) - Rating updated to Market Perform, 05/13/2019 Research - Salem Media (SALM) - First quarter comes in as expected, 05/13/2019 Research - Trovagene (TROV) - First quarter 2019 update, 05/10/2019 Research - Tegna (TGNA) - Raising price target, 05/10/2019 Research - Dyadic (DYAI) - More deals appear likely., 05/10/2019 Research - Cumulus Media (CMLS) - First quarter over delivers, 05/10/2019 Research - One Stop Systems (OSS) - First quarter revenue miss, 05/10/2019 Research - Gray Television (GTN) - Exceeds Q1 Expectations, 05/09/2019 Research - Eagle Bulk Shipping (EGLE) - Another solid quarter of outperformance, 05/09/2019 Research - DLH (DLHC) - Tweaking estimates slightly, 05/09/2019 Research - IEC Electronics (IEC) - Delivering Consistent Organic Growth, 05/09/2019 Research - Harte-Hanks (HHS) - First quarter 2019 update, 05/09/2019 Research - Tribune Publishing (TPCO) - First quarter better than expected, 05/09/2019 Research - Kratos Defense (KTOS) - 1Q19 Above Expectations, 05/09/2019 Research - Townsquare Media (TSQ) - Digital business flourishes, 05/08/2019 Research - Vectrus (VEC) - First quarter 2019 update, 05/08/2019 Research - electroCore (ECOR) - Initiation of Coverage, 05/08/2019 News - Cell Cycle Regulators as Cancer Therapeutics, 05/08/2019 Research - Dyadic (DYAI) - Another licensing agreement, 05/08/2019 Research - Entravision (EVC) - Update on full year 2018 results, 05/08/2019 Research - KeyW (KEYW) - First quarter 2019 results, 05/08/2019 Research - DLH Holdings (DLHC) - Second quarter 2019 Review, 05/08/2019 Research - TherapeuticsMD (TXMD) - First quarter 2019 earnings update, 05/07/2019 Research - Ducommun (DCO) - First quarter 2019 review, 05/07/2019 Research - Endeavour Silver (EXK) - Rating lowered to Market Perform, 05/07/2019 Research - Genie Energy (GNE) - Increasing estimates; strong results, 05/07/2019 Research - Coeur Mining (CDE) - Review of first quarter 2019, 05/03/2019 Research - ACCO Brands (ACCO) - Raising price target, 05/03/2019 News - Game of Thrones: Energy Battles, 05/03/2019 Research - Aurania Resources (ARU.V) - Drilling results analysis, 05/03/2019 Research - Albany International (AIN) - First quarter 2019 review, 05/02/2019 Research - Great Lakes Dredge & Dock (GLDD) - Strong third quarter, 05/01/2019 Research - 1-800-Flowers.com (FLWS) - Fiscal 3Q19 Update, 05/01/2019 Research - Comtech (CMTL) - Analysis of new contract and acquisition, 04/30/2019 Research - Scorpio Bulkers (SALT) - First Quarter 2019 Review, 04/30/2019 Research - Dyadic (DYAI) - Expanding partnership portfolio, 04/30/2019 Research - TherapeuticsMD (TXMD) - Assumption of Coverage, 04/29/2019 Research - Coeur Mining (CDE) - Updating estimates, 04/26/2019 Research - Genprex (GNPX) - Initiation of Coverage, 04/26/2019 News - Tax Cuts and Jobs Act: Are we better off?, 04/26/2019 News - Blockchain for Business: Worth the Hype?, 04/25/2019 Research - KeyW (KEYW) - Announces Definitive Merger Agreement, 04/23/2019 Research - Aurania Resources (ARU:CA) - Appoints new CFO, 04/23/2019 News - Uranium Imports: Trade War Goes Nuclear, 04/22/2019 News - Does A 70% Top Marginal Tax Rate Make Sense?, 04/18/2019 News - Boeing 737 MAX: Is it safe to fly? , 04/17/2019 Research - Avino Silver & Gold (ASM) - Mine exploration provides optimism, 04/17/2019 Research - Sierra Metals (SMTS) - Full year projection estimates, 04/17/2019 Research - Vectrus (VEC) - Award is a big win, 04/17/2019 IPO Podcast Series: Drug Disruption, 04/16/2019 Research - Cumulus Media (CMLS) - , 04/16/2019 Research - Coeur Mining (CDE) - First quarter production results, 04/15/2019 Research - Endeavour Silver (EXK) - Waiting for a turnaround, 04/15/2019 Research - Dyadic (DYAI) - Nasdaq Up-Listing Approved, 04/15/2019 Research - Scorpio Bulkers (SALT) - Liquidity boost; adjusting estimates, 04/12/2019 Research - Great Panther Silver (GPL) - Production numbers slightly lower than expected, 04/11/2019 Research - Aurania Resources (ARU:CA) - Another promising copper target, 04/10/2019 News - Could renewables supply 50% of all generation? How about 80%?, 04/05/2019 Research - One Stop Systems (OSS) - Initiation of Research Coverage, 04/04/2019 News - Stock Buybacks: Good, evil, or maybe something in between?, 04/03/2019 Research - Prize Mining (PRZ:CA) - Behind the recent deal, 04/03/2019 Research - Aurania Resources (ARU:CA) - Updates on copper production, 04/03/2019 News - Macular Edema: The search for the cure continues, 04/02/2019 Research - Trovagene (TROV) - Update on data readout, 04/02/2019 Research - Trovagene (TROV) - Updated prostate cancer data, 04/02/2019 Research - Sierra Metals (SMTS) - 2018 full year recap, 04/01/2019 Research - Albany International (AIN) - Appoints new CFO, 04/01/2019 Research - Pyxis Tankers (PXS) - 2018 financial update, 03/29/2019 Research - Dyadic (DYAI) - 2018 full year update, 03/28/2019 Podcast Launch: The Science of Investing in Biotechs, 03/28/2019 A Video Introduction to Enochian Biosciences, 03/28/2019 Official Trailer: NEW Podcast Series- Icons of Business, Leaders of Emerging Companies, 03/26/2019 Research - Information Services (III) - Favorable risk/reward moving forward, 03/25/2019 Research - Torchlight Energy - Strong updates on project estimates, 03/25/2019 Research - 1-800-Flowers.com (FLWS) - Investor Day Highlights, 03/25/2019 Research - Prize Mining (PRZ:CA) - Initiation of Research Coverage, 03/25/2019 News - The Case for Dr. Copper: New Sources of Demand are Positive for Copper, 03/25/2019 Research - Cumulus Media (CMLS) -- Raising Price Target, 03/22/2019 Research - Pangaea Logistics (PANL) - Business Model/Strategy Shine, 03/22/2019 Research - Seanergy (SHIP) - What do the results show?, 03/21/2019 Research - E.W. Scripps - Analysis of recent acquisitions, 03/21/2019 Research - ProMIS Neurosciences (PMN:CA) - Potential opportunity in Alzheimer's , 03/21/2019 Research - Genie Energy (GNE) - Initiation Report, 03/20/2019 Research - E.W. Scripps (SSP) - Acquiring stations, building portfolio, 03/20/2019 Research - Tegna (TGNA) - Acquisition highlights, 03/20/2019 Research - Information Services (III) - 2019 growth possibilities, 03/18/2019 Research - Tribune Publishing (TPCO) - Behind the numbers , 03/18/2019 Research - Harte-Hanks (HHS) - The focus towards growth, 03/15/2019 Research - Information Services (III) - Q4 review; the full story, 03/15/2019 News - Artificial Intelligence: Can an algorithm do what you do?, 03/14/2019 Research - Townsquare Media (TSQ) - Quarter over delivers, 03/14/2019 Research - Tribune Publishing (TPCO) - Looking forward into 2019, 03/14/2019 Research - KeyW (KEYW) - What will drive 2019 performance?, 03/13/2019 Research - Townsquare Media (TSQ) - Revenues surprise, 03/13/2019 Research - Salem Media (SALM) - Looking past the first quarter 2019, 03/13/2019 Research - Energy Fuels (UUUU) - Updating estimates, 03/13/2019 News - CRISPR-Cas9: Editing away sickness, 03/13/2019 Research - Gannett (GCI) - Favorable risk/reward, 03/12/2019 Research - Comtech Telecommunications (CMTL) - Deeper dive in 2Q19 results, 03/12/2019 Research - Euroseas (ESEA) - Lowering Price Target, 03/12/2019 Research - Aurania Resources (ARU:CA) - New drilling has commenced, Funding secured, 03/11/2019 Research - Great Lakes Dredge (GLDD) - Investor Meeting Highlights, 03/11/2019 News - Green New Deal: Environment Savior or Economy Destroyer?, 03/08/2019 Research - McClatchy (MNI) - Outlook for 2019, 03/08/2019 Research - Trovagene (TROV) - 2018 full year update, 03/08/2019 News - Do We Need to Prepare for War in Space?, 03/07/2019 Research - Eagle Shipping (EGLE) - Long-term outlook positive, 03/07/2019 Research - Comtech (CMTL) - Exceeds 2Q quarterly expectations, 03/07/2019 Research - Kratos Defense (KTOS) - Drone prospect takes flight, 03/07/2019 News - DNA Data Storage: The Future of Informatics, 03/06/2019 Research - Genco Shipping (GNK) - 4Q18 Results Surprise , 03/06/2019 Research - E.W. Scripps (SSP) - Raising Price Target, 03/05/2019 NobleConXV Panel - Marketing Early-Stage Natural Resource Companies to Investors, 03/05/2019 Research - Tegna (TGNA) - Looking towards subscriber growth in 2019, 03/04/2019 Research - Great Panther Silver (GPL) - Expectations in line, 03/04/2019 Research - Kratos Defense (KTOS) - Acquisition announced, 03/01/2019 Research - Gray Television (GTN) - 2018 full year results, 03/01/2019 Research - Avino Silver (ASM) - Increasing 2019 estimates, 03/01/2019 Research - Ducommun (DCO) - 2018, the inflection year, 03/01/2019 News - Merger Mania Hits the Mining Space, 03/01/2019 News - Electric Cars: Time to plug in?, 02/28/2019 News - Could the US Have More Oil than the Saudis?!, 02/27/2019 News - Cannabiz: Growing Like a Weed, 02/26/2019 Research - Cumulus Media (CMLS) - Earnings preview, 02/26/2019 News - Legalizing Sports Gambling: Place Your Bets, 02/25/2019 News - Alzheimer’s, Cannibals, and the Scientist Who Saw the Connection, 02/22/2019 Research - Cumulus Media (CMLS) - Raising price target, 02/14/2019 News - High-yield bonds: Trash or Treasure?, 02/13/2019 News - Trump vs Obama: Who did the first two years better?, 02/12/2019 A MUST WATCH - panel of key opinion leaders - a cure for diabetes, 02/11/2019 The business of cannabis - WATCH an industry panel break it all down, 02/11/2019 WORTH READING - Electric Cars, OPEC Today, FED Impact, 02/11/2019 Channelchek in Forbes - referenced as a gatekeeper for emerging growth companies, 02/11/2019 NobleConXV Keynote Address, 02/05/2019 NobleConXV Webcasts, 02/04/2019 News - The Great Wall of America, 01/24/2019 News - Is OPEC still king of oil?, 01/24/2019 News - End of an Era: Sears Struggles to Survive, 01/23/2019 News - Buybacks: Who benefits?, 01/21/2019 News - Robinhood: Could it steal customers from the banks?, 12/31/2018 News - Holiday Havoc: Why December turned into a tough time for investors, 12/27/2018 News - The Fed raised its rates, now what?, 12/19/2018 News - Polo-like kinases inhibitors are novel drug targets of cancer therapeutics, 12/14/2018 News - Can manufacturing keep up with demand for biologic drugs?, 12/04/2018 News - HIV - Could there be a cure?, 12/01/2018 News - Gold - Trending Up?, 11/27/2018 Welcome to Channelchek video, 11/20/2018 News - Cancer - Harnessing the power of immune system, 11/15/2018 News - Cancer - Gene therapy, what the future holds, 11/15/2018 News - Alzheimer’s - The race to a better treatment, 11/15/2018 News - Trump – Is he right to withdraw from INF?, 11/15/2018 News - Cancer – Is combination therapy the answer?, 11/15/2018My Favorites
